NASDAQ · ACIU
AC Immune SA financials
$2.60−0.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 | Q4 '20 Dec 31 | Q4 '19 Dec 31 | Q4 '18 Dec 31 | Q4 '17 Dec 31 | Q4 '16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — | — | — | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| Diluted shares | 100.8M | 99.7M | 84.7M | 83.6M | 75.0M | 71.9M | 71.1M | 61.8M | 57.1M | 50.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.8M | $40.2M | $93.3M | $31.6M | $90.2M | $160.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $65.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $194.4M | $255.6M | $217.4M | $185.9M | $286.8M | $238.7M |
| Total liabilities | $137.8M | $131.3M | $26.4M | $16.9M | $32.3M | $23.3M |
| Shareholders' equity | $56.6M | $124.3M | $191.0M | $169.0M | $254.4M | $215.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology